Pull to refresh
Logo
What Changed
Following Why Sign Up
CBP suspends de minimis exemption for mail shipments, tightening prescription imports

CBP suspends de minimis exemption for mail shipments, tightening prescription imports

Rule Changes

CBP moves formal-entry deadline to January 20, 2027 and adjusts Entry Type 13 test; Canadian pharmacy group says relief lasts only until then.

October 22nd, 2026: Original October 22 deadline for formal entry on regulated mail

Overview

Updated Oct 24

CBP has pushed the formal customs entry requirement for prescription drugs and other regulated mail to January 20, 2027, 90 days after the original October 22 deadline. The underlying suspension of the $800 de minimis exemption for postal arrivals remains in place.

CBP also changed its Entry Type 13 test on October 22. The electronic filing route for mail valued at $2,500 or less can now accept entries with or without electronic data from other agencies. The Canadian International Pharmacy Association said the delay lets its members serve US customers until January, but repeated that most personal prescription orders will not be workable after that without a policy change.

Why it matters

Americans who buy cheaper prescription drugs from Canadian mail-order pharmacies get 90 more days before new customs rules threaten those deliveries.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$800
De minimis threshold suspended for postal mail
The informal exemption for packages valued at $800 or less no longer applies to international postal arrivals. CBP's October delay did not change that.
$2,500
Ceiling for Entry Type 13 electronic test
CBP's voluntary electronic entry path covers eligible mail shipments valued at $2,500 or less. On October 22, CBP said filers can submit entries with or without electronic data from other agencies.
2027-01-20
Compliance date for formal entry on regulated mail
Mail shipments subject to another agency's requirements, like FDA-regulated drugs, need formal entry from this date. CBP moved it from October 22, 2026.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Ken Hunter
Ken Hunter
Executive Director, Campaign for Personal Prescription Importation
Told UPI on October 22 that more than 110,000 letters had been sent about the rule and that the 90-day delay offered little comfort
AS
Allison Schuster
White House spokesperson
Defended the administration's approach to the October 22 mail rule in AP reporting from October 8, 2026

Organizations Involved

U.S. Customs and Border Protection
U.S. Customs and Border Protection
Federal Agency
Extended the formal-entry compliance date to January 20, 2027 and modified the Entry Type 13 test to allow entries with or without electronic partner-agency data

The Department of Homeland Security agency that controls imports entering the United States, including international mail.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulator
Will trigger formal entry for FDA-regulated mail shipments starting January 20, 2027

The federal agency whose requirements for regulated products trigger formal entry under the new CBP mail rule.
Maple Leaf Medications
Maple Leaf Medications
Canadian Online Pharmacy
Warning US customers of shipment disruption risk

A Canadian online pharmacy that has publicly warned its US customers about the October 22 customs changes.
Canadian International Pharmacy Association
Canadian International Pharmacy Association
Trade Association
Said the 90-day delay lets member pharmacies serve US customers until January 20, 2027, but its assessment is unchanged that the requirements will disrupt customers after that

The trade association for licensed Canadian pharmacies that ship prescription medicines to US customers.
CP
Campaign for Personal Prescription Importation
Advocacy Group
Said more than 110,000 letters had been sent about the mail rule and the 90-day delay offered little comfort, per UPI on October 22

An advocacy group for Americans who buy prescription medicines from foreign pharmacies.

Timeline

June 2026 October 2026

11 events Latest: October 22nd, 2026 · 2 weeks ago Showing 8 of 11
Tap a bar to jump to that date

  1. Original October 22 deadline for formal entry on regulated mail

    Latest Regulation

    The June 24 rule set this as the compliance date for formal entry on regulated mail. CBP extended the deadline to January 20, 2027.

  2. CBP extends formal-entry deadline to January 20, 2027

    Regulation

    CBP moved the compliance date for formal entry on regulated mail from October 22, 2026 to January 20, 2027, saying importers, brokers and postal operators needed more time to update systems. The de minimis suspension for postal mail remains in effect.

  3. CBP modifies Entry Type 13 test to allow entries without PGA data

    Regulation

    CBP changed the electronic mail-entry test so filers can transmit an entry with or without electronic data from partner government agencies. The test began September 22 and covers mail valued at $2,500 or less.

  4. Advocacy group says 110,000 letters sent on mail rule

    Statement

    Ken Hunter of the Campaign for Personal Prescription Importation told UPI that more than 110,000 letters had been sent by people affected by the rule and that the 90-day delay offered little comfort.

  5. AP reports congressional pressure over prescription mail rule

    Political

    Three Florida Republicans and more than 70 Democrats asked the administration for explanations or amendments to protect Americans relying on foreign medications. Ken Hunter of the Campaign for Personal Prescription Importation cited an Eliquis price comparison, and White House spokesperson Allison Schuster defended the administration's approach.

  6. CIPA says delay only postpones disruption

    Statement

    The Canadian International Pharmacy Association said the 90-day delay lets member pharmacies serve US customers until January 20, 2027, but its assessment is unchanged that the requirements will disrupt most personal prescription orders after that.

  7. Entry Type 13 electronic mail entry test begins

    Regulation

    CBP launched the voluntary Entry Type 13 test for eligible international mail shipments valued at $2,500 or less. The test offers an electronic filing path for shipments that would otherwise need formal entry on October 22, including FDA-regulated drugs.

  8. CIPA warns October 22 customs changes will disrupt US prescription shipments

    Statement

    The Canadian International Pharmacy Association said that without a change in policy or implementation, the arrangements used to deliver most personal prescription orders to US patients will no longer be workable after the October 22 compliance date.

  9. Canadian pharmacies warn US customers of disruption risk

    Statement

    Maple Leaf Medications, Your Canada Drug Store, and LifeRx Pharmacy publish notices about potential delays, refusals, and added customs requirements.

  10. Rule's main provisions take effect

    Regulation

    The de minimis suspension applies to mail arrivals; formal entry requirements for regulated mail phase in with an October 22 compliance date.

  11. CBP publishes interim final rule suspending de minimis exemption for postal mail

    Regulation

    The rule suspends the $800 de minimis exemption for international postal arrivals and creates a new postal informal entry process.

Scenarios

1

Canadian pharmacies halt US-bound prescription shipments

Likely Resolves by Jan 31, 2027

Discussed by: Maple Leaf Medications, Your Canada Drug Store, LifeRx Pharmacy — all warn this outcome is possible

If the formal entry process demands information or compliance steps that foreign pharmacies, postal operators, and brokers cannot easily supply, major Canadian mail-order pharmacies stop serving US customers. The pharmacies' own September warnings suggest they expect this path.

2

Entry Type 13 test keeps prescription mail flowing with added friction

Possible Resolves by Q1 2027

Discussed by: CBP's Federal Register notice describing the voluntary electronic entry test

Eligible filers route mail shipments valued at $2,500 or less through the new electronic Entry Type 13 process instead of paper formal entry. Prescription shipments continue but face longer clearance times, added duties, and more FDA scrutiny. The result is disruption, not a halt.

3

FDA enforcement discretion limits the practical impact

Unlikely Resolves by Q1 2027

Discussed by: FDA personal importation guidance; medisearcher.com analysis

FDA continues releasing most personal-use prescription shipments under its enforcement discretion policy, particularly for serious conditions without domestic alternatives. Combined with the Entry Type 13 path, consumers see longer waits but still receive their medications. The legal baseline was already restrictive, so the rule changes process more than outcomes.

4

Congress presses a delay or amendment before October 22

Deadline passed (Oct 22, 2026)

Discussed by: Three Florida Republicans and more than 70 Democrats who wrote to the administration, per AP (October 8, 2026)

Lawmakers ask the administration to explain the mail rule or carve out protections for personal prescription imports. Any change would need to land before October 22, since the rule takes effect as written on that date. Pharmacies and CIPA say most US-bound prescription shipments become unworkable without such a shift.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

February 2025

China-origin de minimis suspension (February 2025)

The US suspended the de minimis exemption for goods arriving from China, ending the duty-free informal entry path that carried hundreds of millions of e-commerce packages from Temu and Shein into the United States.

Then

Shipping timelines lengthened immediately, and customs processing volumes surged as packages moved to formal entry.

Now

The suspension showed how ending de minimis can reshape an import channel's economics within weeks, forcing sellers to relabel, warehouse in the US, or raise prices.

Why this matters now

The October 2026 rule applies the same tool to international postal mail generally — suspending de minimis and shifting packages to formal entry — which is why it can disrupt prescription shipments even without an explicit ban.

2003–2019

FDA personal importation enforcement discretion (2003–present)

For decades, importing unapproved prescription drugs into the US was technically illegal, but FDA's 2003 guidance (updated 2019) described circumstances where personnel might exercise enforcement discretion — generally personal use of no more than a three-month supply for a serious condition without a domestic alternative.

Then

The gray area let Canadian pharmacy imports flourish as a tolerated practice for US patients.

Now

FDA maintained the position that personal importation of unapproved medicines is generally not permitted and that no automatic right of admission exists.

Why this matters now

The new CBP rule operates on top of this existing legal baseline — FDA admissibility law is unchanged, but the customs-entry environment around it becomes far more structured starting October 22.

Sources

(17)
+11
Federal Register / U.S. Government Publishing Office MediSearcher Maple Leaf Medications Your Canada Drug Store LifeRx Pharmacy WeSearch Federal Register U.S. Customs and Border Protection Canadian International Pharmacy Association U.S. Customs and Border Protection CiberCuba CubaHeadlines Reuters UPI Federal Register / U.S. Government Publishing Office Federal Register Federal Register / U.S. Government Publishing Office